Lucy Godley to Leukemia
This is a "connection" page, showing publications Lucy Godley has written about Leukemia.
Connection Strength
2.587
-
FouNdER mutations confer risk for leukemias. Blood. 2019 06 20; 133(25):2636-2638.
Score: 0.578
-
Genetic predisposition to hematologic malignancies: management and surveillance. Blood. 2017 07 27; 130(4):424-432.
Score: 0.502
-
Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012 Dec 20; 120(26):5247-9.
Score: 0.368
-
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107.
Score: 0.195
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
Score: 0.181
-
Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018 05; 557(7706):580-584.
Score: 0.134
-
Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017 05; 31(5):1226-1229.
Score: 0.122
-
Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016 Oct; 43(5):598-608.
Score: 0.120
-
Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 2016 Mar 24; 127(12):1575-86.
Score: 0.114
-
Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014 Jan; 46(1):17-23.
Score: 0.098
-
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma. 2013 Jan; 54(1):28-35.
Score: 0.089
-
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
Score: 0.067
-
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
Score: 0.019